News

Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...
3 major takeaways from Novo Nordisk's Q1 earnings
Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations ...
Fierce Pharma7d
In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...
Novo Nordisk CEO on earnings, GLP-1 deal with CVS, manufacturing
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...
Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
Obesity Drug Price Wars Heat Up as CVS Picks Novo Over Lilly
The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Novo Nordisk cuts forecasts after replica obesity drugs hit US take-up
Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...
Fierce Pharma1d
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...